Liraglutide reduces oxidative stress and restores heme oxygenase-1 and ghrelin levels in patients with type 2 diabetes: A prospective pilot study

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 2, 2015, Pages 603-606

  Rizzo, Manfredi ^a,b,c   Abate, Nicola ^d   Chandalia, Manisha ^d   Rizvi, Ali A ^c   Giglio, Rosaria V ^a   Nikolic, Dragana ^a   Gammazza, Antonella Marino ^a,b   Barbagallo, Ignazio ^b,e   Isenovic, Esma R ^f   Banach, Maciej ^g   Montalto, Giuseppe ^a   Volti, Giovanni Li ^b,e  

^a UNIVERSITY OF PALERMO   (Italy)

^b Euro Mediterranean Institute of Science and Technology   (Italy)

^c UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^e UNIVERSITY OF CATANIA   (Italy)

^f UNIVERSITY OF BELGRADE   (Serbia)

^g MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CHAPERONIN 60; GHRELIN; GLUTAMATE DEHYDROGENASE; HEME OXYGENASE 1; HEMOGLOBIN A1C; LIPID HYDROPEROXIDE; LIRAGLUTIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FEMALE; HORMONE BLOOD LEVEL; HUMAN; ITALY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK REDUCTION; TREATMENT DURATION; WAIST CIRCUMFERENCE; AGED; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; MIDDLE AGED;

ADULT; AGED; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; GHRELIN; GLUCAGON-LIKE PEPTIDE 1; HEME OXYGENASE-1; HUMANS; HYPOGLYCEMIC AGENTS; LIRAGLUTIDE; MALE; METFORMIN; MIDDLE AGED; OXIDATIVE STRESS; PILOT PROJECTS; PROSPECTIVE STUDIES;

EID: 84922569481     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-2291     Document Type: Article

References (20)

1. Rizzo M, Chandalia M, Patti AM, et al. Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study. Cardiovasc Diabetol. 2014; 13: 49.
2. Cernea S, Raz I. Therapy in the early stage: Incretins. Diabetes Care. 2011; 34 Suppl 2: S264-S271.
3. Nonogaki K, Suzuki M. Liraglutide suppresses the plasma levels of active and des-acyl ghrelin independently of active glucagon-like Peptide-1 levels in mice. ISRN Endocrinol. 2013; 2013: 184753.
4. Rizzo M, Rizvi AA, Sudar E, et al. A review of the cardiovascular and anti-atherogenic effects of ghrelin. Curr Pharm Des. 2013; 19: 4953-4963.
5. Hendarto H, Inoguchi T, Maeda Y, et al. GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases. Metabolism. 2012; 61: 1422-1434.
6. Maritim AC, Sanders RA, Watkins JB 3rd. Diabetes, oxidative stress, and antioxidants: A review. J Biochem Mol Toxicol. 2003; 17: 24-38.
7. Okada K, Kotani K, Yagyu H, Ando A, Osuga JI, Ishibashi S. Effects of treatment with liraglutide on oxidative stress and cardiac natriuretic peptide levels in patients with type 2 diabetes mellitus. Endocrine. 2014 [Epub ahead of print].
8. Pradelles P, Grassi J, Chabardes D, Guiso N. Enzyme immunoassays of adenosine cyclic 3',5'-monophosphate and guanosine cyclic 3',5'-monophosphate using acetylcholinesterase. AnalChem. 1989; 61: 447-453.
9. Nourooz-Zadeh J. Ferrous ion oxidation in presence of xylenol oragne for detection of lipid hydroperoxides in plasma. Methods Enzymol. 1999; 300: 58-62.
10. Hu ML Measurement of protein thiol groups and glutathione in plasma. Methods Enzymol. 1994; 233: 380-385.
11. Zhao H, Kalivendi S, Zhang H, et al. Superoxide reacts with hydroethidine but forms a fluorescent product that is distinctly different from ethidium: Potential implications in intracellular fluorescence detection of superoxide. Free Radic Biol Med. 2003; 34: 1359-1368.
12. Novo G, Cappello F, Rizzo M, et al. Hsp60 and heme oxygenase-1 (Hsp32) in acute myocardial infarction. Transl Res. 2011; 157: 285-292.
13. Wu YL, Huang J, Liu J, et al. Protective effect of recombinant human glucagon-like peptide-1 (rhGLP-1) pretreatment in STZ-induced diabetic mice. J Pept Sci. 2011; 17: 499-504.
14. Cabou C, Campistron G, Marsollier N, et al. Brain glucagon-like peptide-1 regulates arterial blood flow, heart rate, and insulin sensitivity. Diabetes. 2008; 57: 2577-2587.
15. Oeseburg H, de Boer RA, Buikema H, van der Harst P, van Gilst WH, Silljé HH. Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A. Arterioscler Thromb Vasc Biol. 2010; 30: 1407-1414.
16. Bao W, Song F, Li X, et al. Plasma heme oxygenase-1 concentration is elevated in individuals with type 2 diabetes mellitus. PLoS One. 2010; 5: e12371.
17. Rizzo M, Macario AJ, de Macario EC, et al. Heat shock protein-60 and risk for cardiovascular disease. Curr Pharm Des. 2011; 17: 3662-3668.
18. Senda M, Ogawa S, Nako K, Okamura M, Sakamoto T, Ito S. The glucagon-like peptide-1 analog liraglutide suppresses ghrelin and controls diabetes in a patient with Prader-Willi syndrome. Endocr J. 2012; 59: 889-894.
19. Taslimi S, Esteghamati A, Rashidi A, Tavakkoli HM, Nakhjavani M, Kebriaee-Zadeh A. Treatment with pioglitazone is associated with decreased preprandial ghrelin levels: A randomized clinical trial. Peptides. 2013; 40: 89-92.
20. Pavlovi D, Koci R, Koci G, et al. Effect of four-week metformin treatment on plasma and erythrocyte antioxidative defense enzymes in newly diagnosed obese patients with type 2 diabetes. Diabetes Obes Metab. 2000; 2: 251-256.